Celcuity Submits sNDA to FDA for REVTORPYK in Advanced Breast Cancer Treatment

Key Facts

In a move reflecting the acceleration of biotech innovation in addressing complex diseases, Celcuity has announced the submission of a supplemental New Drug Application (sNDA) to the U.S. FDA for REVTORPYK (gedatolisib). According to reports, this drug targets specific types of advanced or metastatic HR+/HER2- breast cancer in patients harboring PIK3CA mutations. The submission follows clinical progression requirements aimed at providing a targeted therapy for patients who have failed previous endocrine treatments.

This regulatory milestone is a significant step for Celcuity as it seeks to expand treatment options for breast cancer patients, given that the HR+/HER2- subtype represents a major portion of diagnosed cases. Per analyst data, the submission is based on clinical results intended to address therapeutic gaps for those who did not respond to prior therapies. Such regulatory milestones are generally viewed as positive catalysts for biotechnology firms, though the application is currently in the early stages of FDA review.

Looking ahead, markets will closely monitor the FDA's response regarding the acceptance of the application and the subsequent review timeline. As of August 26, 2026, specific price data for the instrument is unavailable, meaning the stock's qualitative direction will likely be driven by regulatory progress. Investors are also keeping an eye on upcoming U.S. economic data which may influence broader risk sentiment within the healthcare and biotech sectors.